Exsudative age-related macular degeneration (AMD), cataract, macular pucker MedDRA version: 9.1 Level: LLT Classification code 10015902 Term: Exudative senile macular degeneration of retina MedDRA version: 9.1 Level: LLT Classification code 10007739 Term: Cataract MedDRA version: 9.1 Level: LLT Classification code 10025417 Term: Macular puckering of retina
Conditions
Interventions
Trade Name: Lucentis
Pharmaceutical Form: Injection*
Sponsors
Universitätsklinik für Augenheilkunde und Optometrie, AKH Wien
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Signed informed consent, exsudative age-related macula degeneration, surgery of cataract or ocular surgery including vitrectomy Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Prior/concomitant treatment (laser therapy, vitrectomy, anti-VEGF medication, concurrent ocular inflammation, glaucoma, diabetes mellitus, malignant tumor, women capable of bearing children, intake of cortisone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: to investigate cytokine levels in ocular fluid and blood in patients with exsudative age-related macular degeneration and change during treatment with intravitreal Ranibizumab (Lucentis®);Secondary Objective: to investigate cytokine levels in ocular fluid in control patients, gene analysis of patients with exsudative age-related macular degeneration;Primary end point(s): intraocular VEGF levels at the end of treatment (end of treatment is a clinical decision based on disease activity) | — |
Countries
Austria
Outcome results
None listed